An advisory committee for the Food and Drug Administration (FDA) has voted by a majority to recommend broader access to several peptides, a move that could provide millions of Americans with easier and safer access to these compounds.
The FDA's Pharmacy Compounding Advisory Committee considered whether seven peptides should be added to the Section 503A Bulks List during a two-day hearing. If the FDA ultimately approves the committee's recommendation, licensed compounding pharmacies would be able to prepare these substances for valid prescriptions.
This decision could steer patients away from relying on unregulated online vendors, often described as the "grey market," and toward a more accountable medical pathway, according to Jim LaValle, a clinical pharmacist and chair of the International Peptide Society, who testified at the hearings.
"This was not FDA approval, nor was it a blanket endorsement of every peptide, every use or unrestricted access," LaValle stated. "I have said throughout this process that you do not solve a quality problem by forcing the market underground."
The committee voted in favor of loosening restrictions for six peptides: BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon. These peptides are being considered for various potential therapeutic uses, including treatments for ulcerative colitis, wound healing, inflammatory conditions, obesity, osteoporosis, cerebral ischemia, migraine, trigeminal neuralgia, and insomnia.
Peptides are short chains of amino acids that play a role in regulating bodily functions such as metabolism, growth, and tissue repair. Some are already components of FDA-approved medications, like insulin and GLP-1 drugs for weight loss. However, others remain experimental and have been marketed for wellness or performance purposes.
Experts emphasize that the committee's vote is a recommendation, and the FDA will make the final decision. LaValle stressed that the "right model" for access involves guardrails, qualified clinicians, licensed pharmacies, validated quality testing, and meaningful patient follow-up.
"My hope is that the FDA follows the recommendation with a transparent, science-driven process; establishes clear, peptide-specific standards; and follows the guidance for approving a substance that meets the FDA’s current regulations," LaValle said. This process includes ensuring both the active ingredient and the final product meet quality standards and establishing a system for tracking side effects.
LaValle cautioned that not all peptides have the same level of evidence for safety and efficacy, and advised against self-experimentation or purchasing products sold online as "research use only." He recommended that any consideration of peptide therapy should involve a qualified licensed clinician and a legitimate licensed pharmacy.
"The peptide revolution is here," LaValle noted. "However, don’t expect miracles. Better choices related to diet, exercise, gut health, sleep, stress and managing metabolic health, guided by regular lab assessments, should be the goal."